ALL 0 3 0 3 B-cancer
without 4 11 4 11 O
curative 12 20 12 20 O
options 21 28 21 28 O
for 29 32 29 32 O
therapy 33 40 33 40 B-treatment
, 40 41 40 41 O
including 42 51 42 51 O
those 52 57 52 57 O
not 58 61 58 61 O
eligible 62 70 62 70 O
for 71 74 71 74 O
allogeneic 75 85 75 85 B-treatment
SCT 86 89 86 89 I-treatment

Active 0 6 90 96 O
hepatitis 7 16 97 106 B-chronic_disease
B 17 18 107 108 I-chronic_disease
or 19 21 109 111 O
hepatitis 22 31 112 121 B-chronic_disease
C 32 33 122 123 I-chronic_disease
infection 34 43 124 133 O

Adequate 0 8 134 142 O
cardiac 9 16 143 150 O
function 17 25 151 159 O
defined 26 33 160 167 O
as 34 36 168 170 O
LVSF 37 41 171 175 B-clinical_variable
≥ 42 43 176 177 O
28 44 46 178 180 B-lower_bound
% 46 47 180 181 I-lower_bound
confirmed 48 57 182 191 O
by 58 60 192 194 O
ECHO 61 65 195 199 O

Adequate 0 8 200 208 B-clinical_variable
performance 9 20 209 220 I-clinical_variable
status 21 27 221 227 I-clinical_variable
( 28 29 228 229 O
Lansky 29 35 229 235 B-clinical_variable
or 36 38 236 238 O
Karnofsky 39 48 239 248 B-clinical_variable
score 49 54 249 254 I-clinical_variable
≥50 55 58 255 258 O
) 58 59 258 259 O

Adequate 0 8 260 268 B-clinical_variable
pulmonary 9 18 269 278 I-clinical_variable
function 19 27 279 287 I-clinical_variable
defined 28 35 288 295 O
as 36 38 296 298 O
< 39 40 299 300 O
Grade 41 46 301 306 B-upper_bound
3 47 48 307 308 I-upper_bound
hypoxia 49 56 309 316 B-chronic_disease

Age 0 3 317 320 B-age
1 4 5 321 322 B-lower_bound
to 6 8 323 325 O
24 9 11 326 328 B-upper_bound
years 12 17 329 334 I-upper_bound

Any 0 3 335 338 O
uncontrolled 4 16 339 351 O
active 17 23 352 358 B-chronic_disease
medical 24 31 359 366 I-chronic_disease
disorder 32 40 367 375 I-chronic_disease
that 41 45 376 380 O
would 46 51 381 386 O
preclude 52 60 387 395 O
participation 61 74 396 409 O
as 75 77 410 412 O
outlined 78 86 413 421 O

Are 0 3 422 425 O
more 4 8 426 430 O
than 9 13 431 435 O
4 14 15 436 437 B-lower_bound
months 16 22 438 444 I-lower_bound
from 23 27 445 449 O
transplant 28 38 450 460 B-treatment
( 39 40 461 462 O
6 40 41 462 463 B-upper_bound
months 42 48 464 470 I-upper_bound
at 49 51 471 473 O
infusion 52 60 474 482 B-treatment
) 60 61 482 483 O

Bilirubin 0 9 484 493 B-clinical_variable
< 10 11 494 495 O
2.0 11 14 495 498 B-upper_bound
mg 15 17 499 501 I-upper_bound
/ 17 18 501 502 I-upper_bound
dl 18 20 502 504 I-upper_bound

CD19 0 4 505 509 O
+ 4 5 509 510 O
leukemia 6 14 511 519 B-cancer

CNS3 0 4 520 524 B-chronic_disease
disease 5 12 525 532 I-chronic_disease
that 13 17 533 537 O
is 18 20 538 540 O
progressive 21 32 541 552 O
on 33 35 553 555 O
therapy 36 43 556 563 B-treatment
, 43 44 563 564 O
or 45 47 565 567 O
with 48 52 568 572 O
CNS 53 56 573 576 O
parenchymal 57 68 577 588 O
lesions 69 76 589 596 O
that 77 81 597 601 O
might 82 87 602 607 O
increase 88 96 608 616 O
the 97 100 617 620 O
risk 101 105 621 625 O
of 106 108 626 628 O
CNS 109 112 629 632 B-chronic_disease
toxicity 113 121 633 641 I-chronic_disease

Concurrent 0 10 642 652 O
use 11 14 653 656 O
of 15 17 657 659 O
systemic 18 26 660 668 B-treatment
steroids 27 35 669 677 I-treatment
at 36 38 678 680 O
the 39 42 681 684 O
time 43 47 685 689 O
of 48 50 690 692 O
cell 51 55 693 697 O
infusion 56 64 698 706 O
or 65 67 707 709 O
cell 68 72 710 714 O
collection 73 83 715 725 O
, 83 84 725 726 O
or 85 87 727 729 O
a 88 89 730 731 O
condition 90 99 732 741 O
, 99 100 741 742 O
in 101 103 743 745 O
the 104 107 746 749 O
treating 108 116 750 758 O
physician 117 126 759 768 O
's 126 128 768 770 O
opinion 129 136 771 778 O
, 136 137 778 779 O
that 138 142 780 784 O
is 143 145 785 787 O
likely 146 152 788 794 O
to 153 155 795 797 O
require 156 163 798 805 O
steroid 164 171 806 813 B-treatment
therapy 172 179 814 821 I-treatment
during 180 186 822 828 O
collection 187 197 829 839 O
or 198 200 840 842 O
after 201 206 843 848 O
infusion 207 215 849 857 O

Creatinine 0 10 858 868 B-clinical_variable
< 11 12 869 870 O
2.5 13 16 871 874 B-upper_bound
mg 17 19 875 877 I-upper_bound
/ 19 20 877 878 I-upper_bound
dl 20 22 878 880 I-upper_bound
and 23 26 881 884 O
less 27 31 885 889 O
than 32 36 890 894 O
2.5x 37 41 895 899 B-upper_bound
normal 42 48 900 906 I-upper_bound
for 49 52 907 910 O
age 53 56 911 914 B-age

Diffuse 0 7 915 922 B-cancer
large 8 13 923 928 I-cancer
cell 14 18 929 933 I-cancer
lymphoma 19 27 934 942 I-cancer
or 28 30 943 945 O
other 31 36 946 951 O
high 37 41 952 956 B-cancer
- 41 42 956 957 I-cancer
grade 42 47 957 962 I-cancer
NHL 48 51 963 966 I-cancer
, 51 52 966 967 O
previously 53 63 968 978 O
identified 64 74 979 989 O
as 75 77 990 992 O
CD19 78 82 993 997 O
+ 82 83 997 998 O
including 84 93 999 1008 O
residual 94 102 1009 1017 B-cancer
disease 103 110 1018 1025 I-cancer
after 111 116 1026 1031 O
primary 117 124 1032 1039 B-treatment
therapy 125 132 1040 1047 I-treatment
and 133 136 1048 1051 O
not 137 140 1052 1055 O
eligible 141 149 1056 1064 O
for 150 153 1065 1068 O
autologous 154 164 1069 1079 B-treatment
SCT 165 168 1080 1083 I-treatment

Expected 0 8 1084 1092 B-clinical_variable
survival 9 17 1093 1101 I-clinical_variable
> 18 19 1102 1103 O
12 20 22 1104 1106 B-lower_bound
weeks 23 28 1107 1112 I-lower_bound

Female 0 6 1113 1119 B-gender
study 7 12 1120 1125 O
participants 13 25 1126 1138 O
of 26 28 1139 1141 O
reproductive 29 41 1142 1154 O
potential 42 51 1155 1164 O
must 52 56 1165 1169 O
have 57 61 1170 1174 O
a 62 63 1175 1176 O
negative 64 72 1177 1185 B-pregnancy
serum 73 78 1186 1191 I-pregnancy
or 79 81 1192 1194 I-pregnancy
urine 82 87 1195 1200 I-pregnancy
pregnancy 88 97 1201 1210 I-pregnancy
test 98 102 1211 1215 O
performed 103 112 1216 1225 O
within 113 119 1226 1232 O
48 120 122 1233 1235 B-upper_bound
hours 123 128 1236 1241 I-upper_bound
before 129 135 1242 1248 O
infusion 136 144 1249 1257 O

For 0 3 1258 1261 O
those 4 9 1262 1267 O
patients 10 18 1268 1276 O
who 19 22 1277 1280 O
require 23 30 1281 1288 O
leukapheresis 31 44 1289 1302 B-treatment
for 45 48 1303 1306 O
T 49 50 1307 1308 O
cell 51 55 1309 1313 O
collection 56 66 1314 1324 O
( 67 68 1325 1326 O
i.e. 68 72 1326 1330 O
no 73 75 1331 1333 O
previously 76 86 1334 1344 O
collected 87 96 1345 1354 O
product 97 104 1355 1362 O
exists 105 111 1363 1369 O
) 111 112 1369 1370 O
, 112 113 1370 1371 O
adequate 114 122 1372 1380 O
venous 123 129 1381 1387 O
access 130 136 1388 1394 O
for 137 140 1395 1398 O
apheresis 141 150 1399 1408 O
or 151 153 1409 1411 O
eligible 154 162 1412 1420 O
for 163 166 1421 1424 O
appropriate 167 178 1425 1436 O
catheter 179 187 1437 1445 B-treatment
placement 188 197 1446 1455 I-treatment
, 197 198 1455 1456 O
and 199 202 1457 1460 O
no 203 205 1461 1463 O
other 206 211 1464 1469 O
contraindications 212 229 1470 1487 O
for 230 233 1488 1491 O
leukapheresis 234 247 1492 1505 O

HIV 0 3 1506 1509 B-chronic_disease
infection 4 13 1510 1519 O

Have 0 4 1520 1524 O
no 5 7 1525 1527 O
active 8 14 1528 1534 O
GVHD 15 19 1535 1539 B-chronic_disease
and 20 23 1540 1543 O
require 24 31 1544 1551 O
no 32 34 1552 1554 O
immunosuppression 35 52 1555 1572 B-treatment

Male 0 4 1573 1577 B-gender

Patient 0 7 1578 1585 O
may 8 11 1586 1589 O
be 12 14 1590 1592 O
in 15 17 1593 1595 O
any 18 21 1596 1599 O
complete 22 30 1600 1608 O
response 31 39 1609 1617 O
, 39 40 1617 1618 O
or 41 43 1619 1621 O
patient 44 51 1622 1629 O
may 52 55 1630 1633 O
have 56 60 1634 1638 O
active 61 67 1639 1645 O
disease 68 75 1646 1653 O
but 76 79 1654 1657 O
responding 80 90 1658 1668 O
or 91 93 1669 1671 O
stable 94 100 1672 1678 O
after 101 106 1679 1684 O
most 107 111 1685 1689 O
recent 112 118 1690 1696 O
therapy 119 126 1697 1704 B-treatment

Patients 0 8 1705 1713 O
previously 9 19 1714 1724 O
treated 20 27 1725 1732 O
with 28 32 1733 1737 O
B 33 34 1738 1739 O
cell 35 39 1740 1744 O
directed 40 48 1745 1753 O
engineered 49 59 1754 1764 O
cell 60 64 1765 1769 B-treatment
therapy 65 72 1770 1777 I-treatment

Pregnant 0 8 1778 1786 B-pregnancy

Presence 0 8 1787 1795 O
of 9 11 1796 1798 O
grade 12 17 1799 1804 B-lower_bound
2 18 19 1805 1806 I-lower_bound
- 19 20 1806 1807 O
4 20 21 1807 1808 B-upper_bound
acute 22 27 1809 1814 O
or 28 30 1815 1817 O
extensive 31 40 1818 1827 O
chronic 41 48 1828 1835 B-chronic_disease
GVHD 49 53 1836 1840 I-chronic_disease

Steroids 0 8 1841 1849 B-treatment
for 9 12 1850 1853 O
disease 13 20 1854 1861 O
treatment 21 30 1862 1871 B-treatment
at 31 33 1872 1874 O
times 34 39 1875 1880 O
other 40 45 1881 1886 O
than 46 50 1887 1891 O
cell 51 55 1892 1896 O
collection 56 66 1897 1907 O
or 67 69 1908 1910 O
at 70 72 1911 1913 O
the 73 76 1914 1917 O
time 77 81 1918 1922 O
of 82 84 1923 1925 O
infusion 85 93 1926 1934 O

Uncontrolled 0 12 1935 1947 O
active 13 19 1948 1954 B-chronic_disease
infection 20 29 1955 1964 I-chronic_disease

Under 0 5 1965 1970 O
treatment 6 15 1971 1980 B-treatment
for 16 19 1981 1984 O
GVHD 20 24 1985 1989 B-chronic_disease

Use 0 3 1990 1993 O
of 4 6 1994 1996 O
physiologic 7 18 1997 2008 O
replacement 19 30 2009 2020 O
hydrocortisone 31 45 2021 2035 B-treatment
or 46 48 2036 2038 O
inhaled 49 56 2039 2046 B-treatment
steroids 57 65 2047 2055 I-treatment

beyond 0 6 2056 2062 O
1st 7 10 2063 2066 O
CR 11 13 2067 2069 O
with 14 18 2070 2074 O
relapsed 19 27 2075 2083 O
or 28 30 2084 2086 O
persistent 31 41 2087 2097 O
disease 42 49 2098 2105 O
and 50 53 2106 2109 O
not 54 57 2110 2113 O
eligible 58 66 2114 2122 O
or 67 69 2123 2125 O
appropriate 70 81 2126 2137 O
for 82 85 2138 2141 O
conventional 86 98 2142 2154 O
allogeneic 99 109 2155 2165 O
or 110 112 2166 2168 O
autologous 113 123 2169 2179 B-treatment
SCT 124 127 2180 2183 I-treatment

female 0 6 2184 2190 B-gender

lactating 0 9 2191 2200 O
women 10 15 2201 2206 B-gender

lymphoma 0 8 2207 2215 B-cancer

partial 0 7 2216 2223 O
response 8 16 2224 2232 O
or 17 19 2233 2235 O
no 20 22 2236 2238 O
response 23 31 2239 2247 O
to 32 34 2248 2250 O
prior 35 40 2251 2256 B-treatment
cell 41 45 2257 2261 I-treatment
therapy 46 53 2262 2269 I-treatment

relapsed 0 8 2270 2278 O
after 9 14 2279 2284 O
prior 15 20 2285 2290 B-treatment
autologous 21 31 2291 2301 I-treatment
SCT 32 35 2302 2305 I-treatment

relapsed 0 8 2306 2314 O
after 9 14 2315 2320 O
prior 15 20 2321 2326 B-treatment
cell 21 25 2327 2331 I-treatment
therapy 26 33 2332 2339 I-treatment

subjects 0 8 2340 2348 O
with 9 13 2349 2353 O
documented 14 24 2354 2364 O
CD19 25 29 2365 2369 B-cancer
+ 29 30 2369 2370 I-cancer
B 31 32 2371 2372 I-cancer
cell 33 37 2373 2377 I-cancer
malignancies 38 50 2378 2390 I-cancer
and 51 54 2391 2394 O
no 55 57 2395 2397 O
available 58 67 2398 2407 O
curative 68 76 2408 2416 B-treatment
treatment 77 86 2417 2426 I-treatment
options 87 94 2427 2434 O
( 95 96 2435 2436 O
such 96 100 2436 2440 O
as 101 103 2441 2443 O
autologous 104 114 2444 2454 B-treatment
or 115 117 2455 2457 O
allogeneic 118 128 2458 2468 B-treatment
SCT 129 132 2469 2472 I-treatment
) 132 133 2472 2473 O
who 134 137 2474 2477 O
have 138 142 2478 2482 O
limited 143 150 2483 2490 O
prognosis 151 160 2491 2500 O
( 161 162 2501 2502 O
several 162 169 2502 2509 O
months 170 176 2510 2516 O
to 177 179 2517 2519 O
< 180 181 2520 2521 O
2 181 182 2521 2522 B-upper_bound
year 183 187 2523 2527 I-upper_bound
survival 188 196 2528 2536 O
) 196 197 2536 2537 O
with 198 202 2538 2542 O
currently 203 212 2543 2552 O
available 213 222 2553 2562 O
therapies 223 232 2563 2572 B-treatment
will 233 237 2573 2577 O
be 238 240 2578 2580 O
enrolled 241 249 2581 2589 O

